spacer
home > ebr > Winter 2001
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2001
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of the articles in this issue of EBR  
view
bullet
STRATEGY AND FINANCE
In his review of Real Options Evaluation in Pharmaceutical R&D: A New Approach to Financial Project Evaluation, Dr Roy Drucker, General Manager at Technomark Consulting Services Ltd, welcomes the report and its coverage of an area where sector specific literature is currently thin on the ground  
view
Biotech companies have created increasingly varied and sophisticated business models in an attempt to attract investment. In Venture Capital - Making a Business Out of Biotechnology, Bob Damms, Head of Technology at Merlin Biosciences highlights how VCs have become more selective in identifying those companies with business strategies that are most likely to succeed  
view
Science and Innovation
In Calorimetry Takes the Heat Off Drug Discovery, Dr John Ladbury, Wellcome Trust Senior Research Fellow in the Department of Biochemistry and Molecular Biology at University College London, claims that the recent revolution in calorimetric instrumentation has enabled it to assume a position in the frontline of the battle to develop pharmaceutical products  
view
The potential of intrabodies as a versatile tool for target validation is becoming increasingly apparent. In Intrabodies - Valuable Tools for Target Validation, Dr Kirsten E. Mundt, Business Development, ESBATech AG, explains why  
view
Dr Michael Moore, Chief Scientific Officer and Research Director at Xenova, tracks Recent Progress in Tumour Immunology and Prospects for Therapeutic Intervention, concluding that recent advances in understanding of the immune response to human tumour antigens have strengthened the rationale for immune intervention, at least in some cancers  
view
bullet
Legal, Regulatory and Public Policy
In The Credibility Gap - Intellectual Property Rights, Access to Drugs and Bioterrorism, Henry Dummett, Africa and North America Analyst for World Markets Healthcare, questions whether the US and Canada undermined long-held positions on pharmaceutical IPR in the aftermath of September 11th  
view
The anthrax scares across the US have made bioterrorism a very real threat to the Western world. As governments around the globe are acknowledging the need to be able to deal quickly with bioterrorist attacks, Paul Chaplin, Chief Scientific Officer and Vice President of Research and Development at Bavarian Nordic, considers Smallpox - Preventing the Unthinkable  
view
In UK and European Legislation on Embryonic Stem Cell Research, Crispin Kirkman, Chief Executive of the BioIndustry Association (BIA), looks at how work in this field carries enormous potential in the search for cures for many of the world's diseases, but at the same time, how this potential must be balanced against the need to regulate science in order to keep progress within ethical, political and socially acceptable boundaries  
view
bullet
BIOINFORMATICS
Spurred by the desire to sequence the human genome, the amount of biological data now available for life science research continues to grow exponentially. Pam Hudson, Marketing Communications Specialist for Accelrys Inc. explains how External Solutions Help Organisations Meet Bioinformatics Needs  
view
Our Editor, Dr Helen Abbott, reviews GenomeX - 22nd-24th October 2001, Londo  
view
Keith Chidwick, Consultant at Technomark Consulting Services Limited, provides an overview of Biomics - 19th-21st November 2001, Frankfurt  
view
bullet
REGIONAL UPDATES
In The Biopharmaceutical Sector in the South East of England, Dr Peter Read CBE, Chairman of the Business Development Committee and Board Member of SEEDA, explains that although the South East of England is the setting for much of the research conducted in the bioscience industry, the right business environment, facilities and infrastructure are required to maintain this track record  
view
As the global biotechnology industry has just taken its first steps towards an exponential growth development, Dr Peter Heinrich, CEO of MediGene AG and Co-Founder and Deputy Chairman of the Association of German Biotechnology Companies (VBU), poses the question, The German Biotechnology Industry - Where Does it Stand Globally and What Are the Obstacles to Expansion?  
view
bullet
INTERVIEW
EBR's Editor, Dr Helen Abbott offers A History of Proteomics and Bioinformatics - In Conversation with Professor Denis Hochstrasser, Head of the Central Clinical Chemistry Laboratory at Geneva University Hospital, a Founder of GeneProt, Inc., and Chairman of its Scientific Advisory Board  
view
bullet
INDUSTRY DYNAMICS
In The Business Model - Bridging the Gap Between Technology and Economic Value, Pieter van der Meer, Investment Director and Partner with the Biotechnology Team at Gilde Investment Management, shares his view that technology managers must expand their perspectives in order to find the right business model to capture value  
view
EBR's Editor, Dr Helen Abbott, reviews the 9th Annual BioPartnering Europe Event, which took place between October 14th and 16th 2001 in London  
view
bullet
INTELLECTUAL PROPERTY AND TECH-TRANSFER
Now that biotechnology has changed the drug discovery landscape forever, the pharmaceutical industry depends on innovation, and innovation calls for a strong and effective patent system. Peter Steele, Managing Director at Current Patents Ltd, explains the importance of Seeking Competitive Intelligence from Patents  
view
In The Legal Aspects of Venture Capital Finance in Biotechnology, Hanna Paloheimo and Ben Rapinoja, Lawyers at Borenius & Kemppinen Ltd, predict that competiton within the biotech industry will continue to grow in the future, presenting new challenges to the investors, the companies themselves and their advisors  
view
In the first part of a series of articles, Daniel Pavin, a Solicitor specialising in Intellectual Property and Information Technology Law with UK law firm Taylor Joynson Garrett, answerssome of the frequently asked questions associated with Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements  
view
bullet
DEVELOPMENT AND PRODUCTION
At a time when many companies are turning to drug delivery systems, either to extend the lifetime of a brand product, or to produce a generic version with competitive edge, Dr Ulrich Gerth, Vice President of Equity Corporate Finance at HypoVereinsbank AG ponders The Road Ahead for Drug Delivery  
view
Chris Holmes, Principal of Pharmaceuticals Europe, and Glen Potvin, Managing Consultant, at World Class International warn that firms adhering to the status quo will restrict their ability to deliver accurate and timely safety data, in Periodic Safety Update Reports Help Assure Pharmacovigilance in an Era of Unprecedented Change  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Vaisala launches a completely new probe for the measurement of hydrogen peroxide


More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

Industry Events

BIO-Europe® 2017

6-8 November 2017, Messedamm 26 14055 Berlin Germany

The 23rd annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement